In this installment of Robert MacNeill’s (Covance) column, Robert discusses where to best place specific QC samples within a calibration range for a methodology, and the challenges associated with establishing suitable nominal levels for the internal standard concentration.
In this editorial, Reiner Schulte (Cambridge Institute for Medical Research, UK) discusses the market of flow cytometry analyzers and cell sorters, highlighting some interesting developments in the field of flow cytometry.
With the reality of Brexit already impacting the UK’s clinical trials environment, Zamas Lam (QPS; DE, USA) discusses the effect this will have on bioanalytical research, and suggests 10 questions to ask when relocating UK-based preclinical and bioanalysis research projects.
In this installment of Robert MacNeill’s (Envigo) column, Robert discusses methodologies for small lipids, and why these can be a particularly challenging area of biologics.
In this editorial, we learn about some of the emerging technologies in patient-centric healthcare information systems such as the internet of things and big data technologies that are being used to improve patient care.
This editorial provides an insight into the advancing field of microsampling as a tool to monitor critically ill patients in the clinic, highlighting the need for further development to ensure patients receive the highest quality of care.
This editorial provides an insight into the development of proteomics as a tool for drug and biomarker discovery, pharmacodynamics and protein network elucidation; and where technology may be heading in the future.
All immunogenicity assessments present specific challenges. As a contract research organization (CRO), a major challenge we face is related to the lack of harmonization and standardization. Find out more in this editorial from a team at LGC (Cambridgeshire, UK).
“There are, in essence, two schools of thought that I can perceive when discussions occur on the topic of appropriate purity of the laboratory water and various solvents, additives and reagents for any given stage of a quantitative bioanalytical procedure.” Find out more from Robert MacNeill (Envigo) in this editorial column.
Considerations for developing and validating an LC–MS biomarker assay using the surrogate peptide approach
In this editorial, Timothy Sikorski (GSK; PA, USA), discusses particular considerations for developing and validating LC–MS biomarker assays using the surrogate peptide approach.